Dengue Vaccines Market

Dengue Vaccines Market GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK,
AND OPPORTUNITY ANALYSIS, 2018-2026
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Dengue Vaccines Market – Overview
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions.
Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated
with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses
(DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by controlling the vectors being
borne. Severe dengue was discovered in the 1950s during dengue epidemics in Philippines and Thailand. The disease has
since spread to Asian and Latin America countries and is one of the leading causes of hospitalization and deaths among
children and adults in these regions.
Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine
received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world’s first licensed vaccine for prevention
of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45
years.
India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in
the country. A scientist in India has developed a dengue vaccine that was successfully tested in monkeys. If successful in
human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country.
Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Prevalent Scenario in the Global Dengue Vaccines Market:
Member states in three of the WHO regions regularly report the annual number of dengue
cases. These statistic suggest that the number of dengue cases increased from 2.2 million in
2010 to 3.2 million in 2015. The actual number remains underreported. One recent estimate by
Bhatt et al., (also quoted by the WHO) mentions that there are around 390 million dengue cases
worldwide each year, with number of cases reported increasing each year. In 2015, 2.35 million
cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as
severe dengue that led to 1,181 deaths.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/23
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Dengue Vaccines Market Outlook
There are approximately five vaccine candidates under evaluation in clinical trials, including
other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine
candidates. Also, technological approaches, such as virus-vectored and VLP-based vaccines,
are under evaluation in preclinical studies. In September 2016, Takeda announced the
beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine
is also aimed at prevention against all four dengue virus strains.
View this report @
https://www.coherentmarketinsights.com/ongoing-insight/dengue-vaccines-market-23
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization
focused on assisting its plethora of clients achieve transformational growth by helping
them make critical business decisions. We are headquartered in India, with an office at
the global financial capital in the U.S. Our client base includes players from across all
business verticals in over 150 countries worldwide. We are uniquely positioned to help
businesses around the globe deliver practical and lasting results through various
recommendations about operational improvements, technologies, emerging market
trends and new working methods. We offer both customized and syndicated market
research reports that help our clients create visionary growth plans to provide traction to
their business. We meticulously study emerging trends across various industries at both
the global and regional levels to identify new opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
SECTOR COVERAGE
Healthcare
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL IMAGING
PHARMACEUTICAL
MEDICAL DEVICES
Chemicals & Materials
Bulk Chemicals
Advanced
Materials
Speciality and Fine Chemicals
Green Chemicals
Food Ingredients
© Coherent market Insights. All Rights Reserved
Cosmetic Ingredients
Polymers & Resins
ABOUT COHERENT MARKET INSIGHTS
KEY STATS
RESEARCH SOLUTIONS
FEASIBILITY
STUDIES
GLOBAL
REPORTS
100+
Insights Published Per Year
150+
Consulting Projects Till Date
125+
Clients Worldwide Per Year
110+
COUNTRY
ANALYSIS
CONSULT
PROJECTS
SURVEY
RESEARC
H
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and
food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across
various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our
clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained
growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein.
© Coherent market Insights. All Rights Reserved
To k no w mor e abo ut us , v is it o ur w eb site:
w ww.coh er en tmark etins ig hts.com
THANK YOU
© Coherent market Insights. All Rights Reserved
F or s ales q ueries o r new top ics email u s o n :
s ales@coh er en tmark etins ig hts .co m
Fo r o th er q uer ies co n tact:
Mr. Sh ah
( Man ag er - Bus iness D ev elo pment)
Co herent Mark et Ins ig hts
s ales@coh er en tmark etins ig hts .co m
+1 -2 06 -7 0 1- 67 02

Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it.

Download Report